Tasly Pharmaceutical Group Co., Ltd.
Tasly Pharmaceutical Group Co., Ltd. is a leading Chinese innovative TCM company specializing in cardiovascular and cerebrovascular prescription drugs, headquartered in Tianjin. Listed on the Shanghai Stock Exchange (600535.SH), the group recorded CNY 8.236 billion in total revenue in 2025 with CNY 1.104 billion in net profit, and a robust gross margin of 66.76%. The company's signature products a
Core Business Areas
Industry Rankings
VerityRank Score
Based on market presence, financial scale, operational capacity, and brand strength.
Quick Facts
Headquarters
Tianjin
Founded
1994
Employees
8,000+
Listing
Listed - SSE (600535.SH)
Categories
Data Sources & Methodology
This corporate profile is compiled from publicly available sources including company annual reports, SEC/regulatory filings, official press releases, and verified third-party industry databases. Financial figures reflect the most recent fiscal year disclosures and are cross-validated across multiple independent references.
VerityRank Score is calculated using a proprietary multi-dimensional model evaluating market presence, financial strength, operational scale, innovation capacity, and brand influence. Individual dimension scores are normalized against industry peers and updated quarterly.
Disclaimer: This profile is for informational purposes only. VerityRank makes no warranties regarding completeness or timeliness. This content does not constitute investment advice or endorsement.
Key references: Official Website , Tasly Financial Summary - Investing.com, Tasly Stock Price - Google Finance, Tasly Q1 Revenue Analysis - Drugdu Media